Image For Activity Cover
Mastering Clozapine: Increasing Confidence and Improving Outcomes
Overview

Description 

This 12-week learning collaborative will serve as a virtual community for participants to gain knowledge of evidence-based principles for prescribing clozapine for patients with serious mental illness (SMI). Clozapine can be very rewarding to prescribe, since about half of patients with prior poor treatment response get substantially better with clozapine. This medication can result in major improvements in patients’ functioning and quality of life.  

Program Schedule  

The facilitated 12-week syllabus will be held from September 11, 2023 to December 17, 2023. No content will be released during the week of October 9, and November 20, 2023. 

Please note you must complete all 13 modules in order to claim credit for this course. 

Module Opens 

Week 

Description 

Office Hours 

Sep 4 

0 

Pre-work: Welcome and Introduction 

--- 

Sep 11 

 

Clozapine Overview: Efficacy and Mechanism of Action  

 

Sep 18 

2 

Pharmacokinetics and Interpreting Clozapine levels 

Wed, 9/20 @ 4:00-4:30pm ET 

Sep 25 

 

Hematological Considerations and Side Effects  

 

Oct 2 

4 

Metabolic Considerations and Side Effects  

Wed 10/4 @ 5:00-5:30pm ET 

Oct 16 

5 

Cardiac Considerations and Side Effects  

 

Oct 23 

 

GI Considerations and Side Effects  

Wed, 10/25 @ 4:30-5:00 pm ET 

Oct 30 

7 

Other Side Effects (Sialorrhea, Pneumonia, VTE, Enuresis) 

 

Nov 6 

 

Neurological Side Effects  

 

Nov 13 

9 

Managing Partial Response and Treatment Resistance 

Wed, 11/15 @ 4:00-4:30pm ET 

Nov 27 

10 

Team-based approaches to clozapine (e.g., clozapine clinics) 

Wed, 11/29 @ 4:00-4:30pm ET 

Dec 4 

11  

Measuring side effects 

 

Dec 11 

12 

Presentation of SE monitoring protocol 

Wed, 12/13 @ 3:00-4:00pm ET (1 hour) 

Dec 17 

X 

Program Schedule/Syllabus Ends 

 

Pricing  

FREE - $0 

Learning Objectives  

  • Identify patients who are appropriate candidates for clozapine 
  • Evaluate the balance between clozapine and efficacy for control of psychiatric symptoms with that of common side effects. 
  • Review major organ systems for how to assess and mitigate clozapine side effects 
  • Develop and implement a scale to monitor for side effects for patients taking clozapine. 

Target Audience  

Clinicians that are prescribing clozapine to individuals with SMI. [MD/DO, PMHNP, PMH-RN, PA] 

Instructional Level  

Introductory; Intermediate 

Estimated Time to Complete 

Estimated Duration: 15.0 hours  
Program Start Date: September 11, 2023 
Program End Date: December 17, 2023 

Credit Available Until: February 15, 2024  

How to Earn Credit 

Participants who wish to earn continuing medical education (CME) or a certificate of participation may do so by completing all sections of the course including the program evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (other professions) showing the date of completion and hours earned. 

Continuing Education Credit 

In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Physicians  

The APA designates this blended activity for a maximum of 15.0AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Faculty and Planner Disclosures 

The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.  

Instructor/Planner 

  • Robert O. Cotes, MD. Emory University School of Medicine. Disclosures – Consultant: Saladax Biomedical, HLS Therapeutics (unpaid); Research funding (to institution): Otsuka, Roche, Karuna, Alkermes.  Speaker: Clinical Care Options. 

Planners 

  • John Torous, MD, Beth Israel Deaconess Medical Center. Dr. Torous has no relevant financial relationships to disclose. 
  • Teri Brister, PHD, LPC, National Alliance for Mental Illness. Dr. Brister has no relevant financial relationships to disclose. 
  • Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC, University of Texas School of Nursing. Dr. Rolin has no relevant financial relationships to disclose. 

Accessibility for Participants with Disabilities 

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.  

Summary
Availability: On-Demand
Credit Offered:
No Credit Offered
Contains: 19 Courses
Recommended
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
Powered By